Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014;58(1):364-9.
doi: 10.1128/AAC.01228-13. Epub 2013 Oct 28.

Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China

Affiliations

Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China

Zhijian Zhang et al. Antimicrob Agents Chemother. 2014.

Abstract

China is one of the countries with the highest burdens of multidrug-resistant (MDR) and fluoroquinolone (FQ)-resistant tuberculosis (TB) globally. Nevertheless, knowledge about the prevalence and molecular characterization of FQ-resistant Mycobacterium tuberculosis isolates from this region remains scant. In this study, 138 M. tuberculosis isolates determined by the agar proportion susceptibility method to be resistant to ofloxacin (OFX) were enrolled from a national drug resistance survey of China. All these strains were tested for susceptibility to ofloxacin, levofloxacin, moxifloxacin, gatifloxacin, and sparfloxacin using liquid Middlebrook 7H9 medium. The entire gyrA and gyrB genes conferring FQ resistance were sequenced, and spoligotyping was performed to distinguish different genotypes. Overall, the prevalence of resistance in China was highest for ofloxacin (3.76%), intermediate for levofloxacin (3.18%) and moxifloxacin (3.12%), and lowest for sparfloxacin (1.91%) and gatifloxacin (1.33%). Mutations in the gyrA gene were observed in 89 (64.5%) out of the 138 OFX-resistant M. tuberculosis strains. Positions 94 and 90 were the most frequent sites of mutation conferring FQ resistance on these strains, accounting for high-level FQ resistance. Furthermore, the Beijing genotype showed no association with high-level FQ resistance or distribution in hot spots in the quinolone resistance-determining region (QRDR) of gyrA. Our findings provide essential implications for the feasibility of genotypic tests relying on detection of mutations in the QRDR of gyrA and the shorter first-line treatment regimens based on FQs in China.

PubMed Disclaimer

Similar articles

Cited by

References

    1. World Health Organization 2008. Anti-tuberculosis drug resistance in the world: fourth global report. WHO/HTM/TB/2008.394 World Health Organization, Geneva, Switzerland
    1. Yumo HA, Mbanya D, Kuaban C, Neuhann F. 2011. Outcome assessment of a Global Fund grant for tuberculosis control at the district level in rural Cameroon. Int. J. Tuberc. Lung Dis. 15:352–357 - PubMed
    1. Ginsburg AS, Grosset JH, Bishai WR. 2003. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. 3:432–442. 10.1016/S1473-3099(03)00671-6 - DOI - PubMed
    1. Xu P, Li X, Zhao M, Gui X, DeRiemer K, Gagneux S, Mei J, Gao Q. 2009. Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. Antimicrob. Agents Chemother. 53:3170–3172. 10.1128/AAC.00177-09 - DOI - PMC - PubMed
    1. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox H, Holtz TH, Hollm-Delgado MG, Keshavjee S, Deriemer K, Centis R, D'Ambrosio L, Lange C, Bauer M, Menzies D. 2013. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur. Respir. J. 42:156–168. 10.1183/09031936.00134712 - DOI - PMC - PubMed

Publication types

LinkOut - more resources